Wells Fargo & Company Immuneering Corp Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.91 - $7.32 $1,768 - $6,778	926 Added 15.31%	6,974 $20,000
Q4 2023 Feb 09, 2024	BUY	$4.84 - $8.44 $6,427 - $11,208	1,328 Added 28.14%	6,048 $44,000
Q3 2023 Nov 13, 2023	SELL	$7.21 - $10.68 $25,725 - $38,106	-3,568 Reduced 43.05%	4,720 $36,000
Q2 2023 Aug 15, 2023	BUY	$6.49 - $13.36 $52,971 - $109,044	8,162 Added 6477.78%	8,288 $84,000
Q1 2023 May 12, 2023	BUY	$3.78 - $10.38 $7 - $20	2 Added 1.61%	126 $1,000
Q4 2022 Feb 13, 2023	SELL	$4.09 - $15.0 $4,077 - $14,955	-997 Reduced 88.94%	124 $0
Q3 2022 Nov 14, 2022	BUY	$5.0 - $14.32 $5,330 - $15,265	1,066 Added 1938.18%	1,121 $16,000
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $38,269 - $76,834	-9,838 Reduced 99.44%	55 $0
Q1 2022 May 16, 2022	SELL	$6.47 - $16.99 $1,921 - $5,046	-297 Reduced 2.91%	9,893 $64,000
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $163,553 - $314,728	10,146 Added 23059.09%	10,190 $165,000
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $748 - $1,444	44 New	44 $1,000

9.65M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $70.2M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.